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Introduction
Ubiquitin-mediated  proteolysis  is  fundamental  to  the  proper 
control of mitosis. The anaphase-promoting complex/cyclosome 
(APC/C) ubiquitin ligase ensures the correct ordering of events 
by targeting specific proteins at specific times (Pines, 2006). 
The APC/C responds to the spindle assembly checkpoint (SAC) 
such that it targets securin and cyclin B1 for destruction only 
when all of the chromosomes have attached to the mitotic 
spindle, thereby ensuring that sister chromatids segregate to 
opposite poles and that cells cannot exit mitosis until sister 
chromatids have separated. The SAC prevents the APC/C from 
ubiquitylating securin and cyclin B1 by targeting its coactivator, 
Cdc20 (Musacchio and Salmon, 2007). However, Cdc20 is 
not completely inactivated because it can still work with the 
APC/C to ubiquitylate substrates such as cyclin A, Nek2A, and 
HOXC10 (den Elzen and Pines, 2001; Geley et al., 2001; Hames 
et al., 2001; Gabellini et al., 2003; Wolthuis et al., 2008). How 
APC/C
Cdc20 is able to recognize some substrates independently 
of the SAC but not others is crucial to our understanding of how 
the APC/C and SAC cooperate to ensure genomic stability.
One important insight is that the N terminus of Cdc20 is 
able to activate the APC/C in Xenopus laevis egg extracts (Kimata 
et al., 2008) to recognize the Nek2A protein that binds directly to 
the APC/C (Hayes et al., 2006). An analogous mechanism may 
underlie the degradation of cyclin A, which requires the Cks pro-
tein to be degraded (Swan et al., 2005; Wolthuis et al., 2008). Cks 
proteins contain an anion-binding pocket implicated in binding 
to phosphoproteins (Bourne et al., 1996), including the APC/C   
(Sudakin et al., 1997), whose phosphorylation by cyclin B1–Cdk 
at mitosis is crucial to its activity (Kraft et al., 2003). Because 
some cyclin A bound Cdc20 before mitosis, we proposed that its 
associated Cks subunit might direct the Cdc20–cyclin A complex 
to the newly phosphorylated APC/C, thereby triggering cyclin A 
destruction at mitotic entry (Wolthuis et al., 2008), but at that 
time, we did not have any experimental proof for this model.
Our model also raised two important questions. First, if the 
Cks subunit does target Cdc20–cyclin A–Cdk to the APC/C, is this 
sufficient for destruction, or does the Cdk contribute? Cyclin A 
cannot be degraded in prometaphase if it can’t bind its Cdk or if 
the Cdk can’t bind Cks (Stewart et al., 1994; den Elzen and 
Pines, 2001; Geley et al., 2001; Wolthuis et al., 2008), but 
whether the requirement to bind a Cdk is solely to recruit Cks is 
not known. The second question is that because only a fraction 
of cyclin A is bound to Cdc20 when cells enter mitosis, how is 
the rest of cyclin A degraded while the SAC is active?
The simplest hypothesis is that cyclin A can compete with 
the SAC proteins to bind Cdc20 and then be recruited to the   
APC/C via Cks. In this study, we provide strong support for this   
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degraded with normal kinetics in a Cdc20-dependent manner 
(Fig. 2 A). Thus, cyclin A does not have to bind to Cdc20 before 
mitosis to be targeted for degradation in an SAC-resistant manner. 
This supports our hypothesis that cyclin A binds to Cdc20 even 
while the checkpoint is active. The first step in the SAC pathway 
is that Mad2 binds to Cdc20 (Musacchio and Salmon, 2007); 
therefore, the simplest mechanism would be that cyclin A and 
Mad2 bind to overlapping regions of Cdc20. But we find that 
cyclin A binds to the WD40 repeat at the C terminus of Cdc20 
(unpublished data), whereas the Mad2-binding region maps to 
the N terminus (aa 124–137; Yu, 2007).
Because cyclin A and Mad2 did not compete for the same 
binding site on Cdc20, we tested the possibility that cyclin A 
could compete with the SAC complex for Cdc20 (note that by 
competition, we include mechanisms by which cyclin A could 
preferentially bind Cdc20 by inducing an allosteric change).   
Because we find only a minor fraction of Mad2 bound to Cdc20 
(Nilsson et al., 2008), we tested whether cyclin A could displace 
BubR1. We immunoprecipitated Cdc20 from nocodazole-treated 
cells, added purified GST fusion proteins, and assayed their   
effect on the integrity of the Cdc20–SAC complex. Consistent 
with our competition hypothesis, excess cyclin A displaced 
BubR1 from Cdc20 (Fig. 2 B), and this depended on its ability to 
interact with Cdc20; full-length cyclin A and the 1–165 fragment 
were both able to displace BubR1, whereas neither the 1–98 frag-
ment of cyclin A nor the N terminus of cyclin B1 containing its D 
box (1–167) could do so (Fig. 2, C and D). We added a large ex-
cess (10–50-fold over Cdc20-coimmunoprecipitated BubR1) of 
the proteins in these in vitro reactions, but it is reasonable to sup-
pose that the in vitro conditions do not recapitulate those in vivo 
and that competition in vivo may be more efficient.
To test whether cyclin A could compete with BubR1 for 
Cdc20 in vivo, we overexpressed cyclin A or cyclin A 1–165 
4–12-fold over endogenous and found that both greatly reduced 
the level of Cdc20 in BubR1 immunoprecipitates (Fig. 2, E and F). 
Thus, we conclude that both in vitro and in vivo, cyclin A is able 
to compete with the SAC proteins for binding to Cdc20, even 
when Cdc20 is already bound to the SAC complex.
Binding to Cdc20 is necessary but not 
sufficient for the proper timing of  
cyclin A degradation
Having identified a region of cyclin A sufficient to bind to Cdc20, 
regardless of whether Cdc20 was free or bound in an SAC com-
plex, we asked whether this was sufficient to target a protein for 
destruction in prometaphase. We used Venus-tagged proteins to 
assay the precise timing of destruction in mitosis and compared 
full-length cyclin A, which is degraded as soon as cells begin 
prometaphase (Fig. 3 A; den Elzen and Pines, 2001; Geley et al., 
2001; Wolthuis et al., 2008), with both the N-terminal fragments 
and a chimeric protein replacing the N terminus of cyclin B1 
with that of cyclin A.
In support of our hypothesis, the N terminus of cyclin A 
conferred the ability to be degraded in an SAC-resistant man-
ner on cyclin B1 (Fig. 3 B), whereas the cyclin A 1–98 frag-
ment that could not bind Cdc20 was not degraded until anaphase   
(Fig. 3, C and D; note that data are plotted twice, once normalized 
hypothesis by showing that cyclin A does not have to bind to   
Cdc20 before mitosis to be degraded because the N terminus of   
cyclin A binds directly to Cdc20 and can outcompete the SAC com-
plex for binding to Cdc20. Furthermore, we show that only Cks, and   
not the Cdk subunit, is required for proteolysis because fusing the   
N terminus of cyclin A to a Cks protein is sufficient to target it to 
the APC/C and confer destruction in an SAC-resistant manner.
Results and discussion
Cdc20 binds directly to the N terminus  
of cyclin A
Previously, we showed that cyclin A bound to Cdc20 in G2 phase 
and that both Cdc20 and Cks were required for its degradation 
(Wolthuis et al., 2008). However, we did not determine the mecha-
nism by which cyclin A could be degraded in an SAC-resistant 
manner. To address this question, we first sought to identify the 
regions of cyclin A required to bind to Cdc20.
An extended sequence in the N terminus of cyclin A is   
required to target cyclin A for degradation in prometaphase   
(den Elzen and Pines, 2001; Geley et al., 2001; Jacobs et al., 2001). 
We generated several cyclin A deletion mutants (Fig. 1 A) tagged 
at the C terminus with the Flag epitope and a fluorescent protein 
(Venus; Nagai et al., 2002). As a control, we used cyclin B1, 
which is degraded in an SAC-sensitive manner (Clute and Pines, 
1999). To ensure that the proteins were expressed at close to en-
dogenous levels, we generated stable inducible HeLa cell lines 
in which a single copy of the plasmid was integrated into the ge-
nome at a flippase recognition target (FRT) site. The proteins 
were  immunoprecipitated  from  prometaphase  cells  using  an 
anti-Flag antibody and probed for Cdc20 and Cdk2. As expected, 
the N-terminal fragments lacking the cyclin box could not bind 
Cdk2 (Fig. 1, B and C).
Consistent with our previous findings (Wolthuis et al., 
2008), cyclin A, but not cyclin B1, strongly bound to Cdc20, but 
neither the N-terminal fragment (1–98) containing the extended 
motif required for cyclin A degradation nor the complementary 
mutant N97 were able to bind Cdc20 (Fig. 1, B and C), indicat-
ing that a more complex region was required. A longer N-terminal 
fragment, 1–165, did bind Cdc20 to a similar extent as full-length 
cyclin A (Fig. 1, B and C), which is in agreement with results from 
a yeast two-hybrid analysis (Ohtoshi et al., 2000). Moreover,   
cyclin A and Cdc20 bound directly to each other (Fig. 1 D).
Complementing these data, an internal deletion that re-
moved  the  extended  D-box  motif  (47–83)  abrogated  Cdc20 
binding (Fig. 1, B and C) when expressed at similar levels to en-
dogenous cyclin A. We conclude that the extended D-box motif 
contributes to Cdc20 binding, but is not itself sufficient, and that 
another region between residues 98 and 165 is required.
Cyclin A competes with BubR1 for  
Cdc20 binding
We previously showed that some, but by no means all, cyclin A 
binds to Cdc20 in G2 phase (Wolthuis et al., 2008), raising the 
question of what happened to cyclin A that was not bound to 
Cdc20. To answer this, we injected purified cyclin A–GFP–Cdk2 
lacking Cdc20 into prometaphase cells and found that this was 503 How cyclin A destruction escapes the checkpoint • Di Fiore and Pines
SAC is satisfied. Therefore, binding directly to Cdc20 is not in 
itself sufficient to confer SAC-resistant proteolysis. Thus, addi-
tional factors must contribute to the SAC-resistant degradation 
of cyclin A.
Cks1 is essential to mediate checkpoint-
resistant degradation
To identify the missing component that confers SAC-resistant 
destruction, we focused first on the Cks protein because full-
length cyclin A must bind to its Cdk partner and consequently 
to Cks to be degraded (Wolthuis et al., 2008). Moreover, the 
N terminus of cyclin A was sufficient to confer SAC-resistant 
to nuclear envelope breakdown [NEBD] and once to anaphase). 
In contrast, the 1–165 fragment that bound Cdc20 was degraded 
earlier, but notably, this was in metaphase not prometaphase (Fig. 3, 
E and F). Because metaphase equates to when the SAC has been 
satisfied, we tested whether this destruction was under the control 
of the SAC. We depleted Mad2 to inactivate the SAC and found 
this advanced cyclin A (1–165) degradation to begin just after 
NEBD (Fig. 3, I and J), which is consistent with regulation by 
the SAC. In contrast, degradation of the 1–98 fragment was still 
delayed until anaphase (Fig. 3, G and H).
We conclude that although the 1–165 fragment can com-
pete with BubR1 for Cdc20, it can only be degraded when the 
Figure 1.  The N terminus of cyclin A binds Cdc20. (A) Schematic representation of cyclin A mutants. (B) Stable inducible HeLa FRT cell lines expressing 
cyclin B1, and the cyclin A mutants were synchronized in mitosis by a single thymidine block and released in the presence of nocodazole. To prevent cyclin A 
degradation, MG132 was added 2 h before collecting mitotic cells by shake off. Cells were lysed, and anti-Flag immunoprecipitates (IP) were probed for 
Cdc20, Cdk2, and Flag. (C) Cdc20 and Cdk2 levels in the anti-Flag immunoprecipitates (B) were quantified using an Odyssey scanner, corrected for the 
level of Flag-tagged protein, and normalized to the amount bound to wt cyclin A. Error bars indicate mean ± SEM from three experiments. (D) GST–cyclin A   
was purified from bacteria and incubated for 2 h at 4°C with His6-Cdc20 purified from insect cells. Cyclin A was isolated on glutathione beads, and the 
beads and supernatants (SPN) analyzed by immunoblots were probed for Cdc20 and GST. Values are representative of seven experiments. Molecular 
mass markers are shown on the left (kilodaltons).JCB • VOLUME 190 • NUMBER 4 • 2010   504
anaphase (Fig. 4, A and B). Similarly, fusing Cks1 to the N terminus 
of cyclin B1 that cannot bind Cdc20 when the SAC is active did not 
change the timing of its destruction to prometaphase, although it 
made it a more efficient substrate (unpublished data; see van Zon 
et al. in this issue).
These  results  demonstrate  that  Cks1  is  sufficient  to 
confer SAC-resistant degradation on a cyclin A–Cdc20 com-
plex, bypassing any requirement for Cdk binding or activity   
(Fig. S1, A and B). Thus, the primary reason why cyclin A has 
to bind to its Cdk to be degraded is to be targeted to the APC/C 
via the Cks protein.
degradation on cyclin B1 (Fig. 3 B) that binds Cks via its Cdk1 
partner. However, it was unclear whether the Cdk subunit itself 
contributed to the destruction of cyclin A.
Because we hypothesized that the role of Cks was to bind 
the APC/C, we predicted that we could bypass the Cdk and target 
the cyclin A 1–165 fragment for degradation even in the presence 
of an active SAC by fusing it to a Cks protein. In confirmation of 
this, a cyclin A (1–165)–Venus-Cks1 fusion protein was degraded 
just after NEBD (Fig. 4, C and D) with the same timing as wild-
type (wt) cyclin A. Furthermore, fusing Cks1 to cyclin A (1–98) 
that could not bind Cdc20 had no effect; it was still degraded in 
Figure 2.  Cyclin A competes with BubR1 for 
binding to Cdc20. (A) The cyclin A–GFP–Cdk2 
complex was purified from baculovirus-infected 
insect  cells  and  injected  into  prometaphase 
HeLa cells identified by DIC (top). Time is rela-
tive to time of injection (min). Bar, 10 µm. GFP 
fluorescence  through  mitosis  was  measured 
(bottom) for normal (black curve) and Cdc20-
depleted (gray curve) cells and set to 100 at 
the time of injection. Error bars indicate mean ± 
SD of 22 cells from two experiments (control) 
and 26 cells from two experiments (siCdc20). 
(B)  Cdc20  bound  in  the  SAC  complex  was 
immunoprecipitated  (IP)  with  anti-Cdc20  anti-
bodies  from  nocodazole-arrested  cells  and 
incubated  with  GST  alone  or  GST–cyclin  A 
for  2  h  at  4°C.  The  supernatant  (SPN)  was 
removed and analyzed by immunoblotting for 
BubR1, Cdc20, and GST. Black line indicates 
that intervening lanes have been spliced out. 
(C)  Cdc20  immunoprecipitates  (obtained  as 
in B) were incubated with buffer (mock), GST, 
the indicated GST–cyclin A mutants, or GST– 
cyclin  B1  (1–167)  and  analyzed  as  in  B.   
(D) The amount of BubR1 released from the 
immunocomplex (C) was quantified using an 
Odyssey scanner, corrected for the amount of 
Cdc20 immunoprecipitated and normalized to 
that released by wt cyclin A. Error bars indicate 
mean ± SEM from at least five experiments.   
(E)  Stable  cell  lines  expressing  either  Venus 
alone, cyclin A–Venus, or cyclin A (1–165)–
Venus  were  treated  with  nocodazole,  and 
MG132  was  added  2  h  before  lysis.  Anti-
BubR1  immunoprecipitates  were  probed  for 
BubR1, Cdc20, and Venus. (F) The amount of 
Cdc20  associated  with  immunoprecipitated 
BubR1  (E)  was  quantified  as  in  D  and  cor-
rected for the amount of immunoprecipitated 
BubR1  (light  gray).  To  compare  the  wt  and 
1–165  samples,  the  values  were  corrected 
for expression levels, setting the 1–165-Venus 
level to 1 (dark gray). Error bars indicate mean ± 
SEM from four experiments. (B, C, and E) Input 
represents 1/10 of the immunoprecipitation. 
Molecular mass markers are shown on the 
left (kilodaltons).505 How cyclin A destruction escapes the checkpoint • Di Fiore and Pines
proteins (Fig. 4 E, lanes 10–19). Cks increased the processivity   
of cyclin A ubiquitylation because although the amount of 
mono- and oligoubiquitin species (one to five ubiquitins) was 
similar for the two substrates (Fig. 4 F), the proportion of poly-
ubiquitin chains was higher for the Cks1 fusion (Fig. 4 G). More-
over, cyclin A (1–165)–Cks1 was clearly a better competitor in   
Fusion to Cks1 promotes  
cyclin A ubiquitylation
If Cks does target cyclin A to the APC/C, one might predict 
that it should enhance cyclin A ubiquitylation. Therefore, we 
compared the in vitro ubiquitylation of cyclin A (1–165)– 
Venus (Fig. 4 E, lanes 1–9) and cyclin A (1–165)–Venus-Cks1   
Figure 3.  Binding to Cdc20 only confers SAC-
dependent destruction.  (A)  HeLa  cells  were  in-
jected  in  G2  phase  with  cyclin  A–Venus-Flag, 
and  the  fluorescence  was  measured  through 
mitosis.  Fluorescence  at  NEBD  is  set  to  100.   
Error bars indicate mean ± SD of 36 cells. Time 
is relative to NEBD. (B) Mean degradation curve 
of a chimera between the N terminus of cyclin A 
(1–165) and C terminus of cyclin B1 (171–433) 
obtained as in A in the absence (black curve) 
or  presence  (gray  curve)  of  nocodazole.  Error 
bars indicate mean ± SD of 49 cells from three 
experiments (untreated) and 27 cells from two 
experiments  (nocodazole).  (C–F)  Mean  deg-
radation  curve  of  cyclin  A  (1–98)–Venus-Flag   
(C  and  D)  and  cyclin  A  (1–165)–Venus-Flag   
(E and F) obtained as in A. Time is relative to 
NEBD (C and E) or anaphase (D and F), and 
fluorescence at NEBD or anaphase is set to 100. 
Error bars indicate mean ± SD of 12 cells from 
three experiments (C and D) and 36 cells from 
three experiments (E and F). (G–J) Mean deg-
radation  curve  of  cyclin  A  (1–98)–Venus-Flag   
(G  and  H)  and  cyclin  A  (1–165)–Venus-Flag   
(I and J) in Mad2-depleted cells were obtained 
as in A except that the Mad2 siRNA oligonucleo-
tides  were  transfected  during  synchronization. 
Because  inactivating  the  SAC  accelerates  pro-
gression from NEBD to anaphase (not depicted; 
Meraldi et al., 2004), we only considered those 
cells in which NEBD to anaphase was shortened 
from  the  40  min  in  control  cells  to  <20  min. 
Time is relative to NEBD (G and I) or anaphase   
(H and J). Error bars indicate mean ± SD of 10 
cells (G and H) and 13 cells from three experi-
ments (I and J).JCB • VOLUME 190 • NUMBER 4 • 2010   506
Figure 4.  Cyclin A–associated Cks1 increases the efficiency of cyclin A ubiquitylation. (A–D) Cells were injected in G2 phase with cyclin A (1–98)–Venus-Cks1 
(A and B) or cyclin A (1–165)–Venus-Cks1 (C and D), and the fluorescence was measured through mitosis. Time is relative to NEBD (A and C) or anaphase   
(B and D). Error bars indicate mean ± SD of 19 cells from two experiments (A and B) or 24 cells from two experiments (C and D). (E) In vitro ubiquitylation 
assay of cyclin A (1–165)–Venus (lanes 1–9) or cyclin A (1–165)–Venus-Cks1 (lanes 10–19). Reactions were performed for the indicated time (shown in 
minutes) before analysis by SDS-PAGE and phosphoimaging. Control reactions are without APC/C (lanes 9 and 18) or E2 (lane 19). (F and G) Quantification of 
ubiquitin conjugates in E with one to five ubiquitin (F) and more than five ubiquitin (G) molecules were normalized to the total amount of ubiquitylated substrate.   
(F and G) Error bars indicate mean ± SEM from four experiments. (H) Ubiquitylation reactions for cyclin A (1–165)–Venus (lanes 1–4) and cyclin A (1–165)– 
Venus-Cks1 (lanes 5–8). 100 times excess of unlabeled cyclin A (1–165)–Venus (lanes 3 and 7) or cyclin A (1–165)–Venus-Cks1 (lanes 4 and 8) was added 
as a competitor at the beginning of the reaction. (I) Quantification of reactions in H. Numbers correspond to lanes in H. *, unmodified substrate; **, P < 0.01;   
***, P < 0.05 (calculated using Student’s t test).507 How cyclin A destruction escapes the checkpoint • Di Fiore and Pines
binding to a Cdk was not affected (Fig. 5, A and B; and not 
depicted). When fused to cyclin A (1–165), Cks1 (R20A) was 
unable to confer SAC-resistant degradation; like the 1–165 
fragment alone, the R20A fusion protein could only be degraded 
in metaphase once the SAC was satisfied (Fig. 5, C and D). 
Thus, the anion-binding site of Cks1 was essential to confer 
in vitro APC/C-dependent ubiquitylation reactions than cyclin A   
(1–165; Fig. 4, H and I).
To test whether the Cks protein had to bind to the APC/C 
to promote cyclin A degradation in vivo, we mutated the anion-
binding site of Cks1 (R20A; Watson et al., 1996). This mutant 
was severely disabled in its ability to bind to the APC/C, whereas 
Figure 5.  Cks directly recruits cyclin A to the APC/C. (A) Purified His6-Cks1 and an anion-binding site mutant (R20A) and fusion proteins between cyclin A 
(1–165)–Venus and wt or (R20A) mutant Cks1 were immobilized on beads and incubated with extract from nocodazole-treated HeLa cells. Beads were 
analyzed by SDS-PAGE and immunoblotted for APC3, cyclin A, and Cks1. Molecular mass markers are shown on the left (kilodaltons). (B) APC3 binding 
to Cks1 (A) was quantified on an Odyssey scanner and corrected for the amount of Cks1. Values were normalized to wt Cks1. Error bars indicate mean ± 
SEM from three experiments. (C and D) Degradation of cyclin A (1–165)–Venus-Cks1 (R20A) measured as in Fig. 4 (A and B). Time is relative to NEBD (C) 
or anaphase (D). Error bars indicate mean ± SD of 28 cells from two experiments. (E) Working model. The cyclin A–Cdk–Cks complex binds to soluble or 
APC/C-associated Cdc20 by out competing the SAC complex. Recruitment to the APC/C is mediated by Cks interaction with phosphorylated APC/C.JCB • VOLUME 190 • NUMBER 4 • 2010   508
Fusions between cyclin A fragments and Cks1 were constructed in modi-
fied versions of the pEYFP-N1 plasmid, resulting in the YFP/Venus sequence 
expressed between cyclin A and Cks1. For the cyclin A-B1 fusion protein, 
cyclin A N terminus (aa 1–165) was fused to the C terminus of cyclin B1 
(aa 171–433) in a modified version of pEYFP-N1 plasmid. For protein 
purification, pGEX (GE Healthcare), a modified version of pET30a (EMD) 
containing a strep tag, and pRSET (Invitrogen) vectors were used.
Microinjection and time-lapse imaging and analysis
For microinjection and time-lapse microscopy, the culture medium was re-
placed with Leibovitz’s L-15 medium (Invitrogen). Plasmids or recombinant 
protein were microinjected into G2 or prometaphase cells, respectively,   
using a semiautomatic microinjector (Eppendorf) on a microscope (DMIRBE 
or DMIRE2; Leica). Differential interference contrast (DIC) and fluorescence 
images were captured every 3 min with a charge-coupled device camera 
(QuantEM 512B; Photometrics) using Slidebook software (Intelligent Imag-
ing Innovations). A modified version of ImageJ software (National Institutes 
of Health) was used to quantify the fluorescence after background subtrac-
tion. DIC microscopy was used to monitor mitotic phases.
RNA interference
siRNA duplex against Mad2 (5-GGAAGAGUCGGGACCACAGUU-3; 
Thermo Fisher Scientific), Cdc20 (5-CGGAAGACCTGCCGTTACA-3; 
Thermo Fisher Scientific), and control siRNA duplex against GAPDH   
(Applied Biosystems) were transfected at a final concentration of 100 nM 
with Oligofectamine (Invitrogen) according to the manufacturer’s protocol. 
Transfection was performed during synchronization 5 h after release from 
the thymidine block. For Cdc20, an extra transfection was performed be-
fore starting the synchronization protocol.
Protein expression and pull-downs
Recombinant proteins were induced with 0.5 mM IPTG in BL21 (DE3) at 
25°C for 5 h and purified on glutathione Sepharose 4B beads (GE Health-
care), Strep-Tactin matrix (IBA), or nickel beads (QIAGEN) according to the 
manufacturer’s protocols. His-tagged Cdc20 was purified from baculovirus-
infected Sf9 cells as previously described (Nilsson et al., 2008). For GST 
pull-downs, GST proteins were immobilized on glutathione beads and in-
cubated with purified Cdc20 in buffer A (50 mM Tris-HCl, pH 8.0, 150 mM 
NaCl, 5 mM MgCl2, 5% glycerol, and 1 mM DTT) with 10 µg BSA for 2 h 
at 4°C. For His6-Cks1 and cyclin A–Cks-strep–binding assays, purified pro-
teins were coupled to nickel or Strep-Tactin beads and incubated in buffer 
(50 mM Tris-HCl, pH 7.8, 150 mM NaCl, and 0.2% NP-40) for 2 h at 4°C 
with extracts from nocodazole-treated HeLa cells. For protein microinjection, 
cyclin  A–GFP–His–Cdk2  complex  was  purified  from  baculovirus-infected   
insect cells using nickel beads, and the folding of the purified complex was 
assessed on a gel filtration column (Superdex 200; GE Healthcare).
Immunoprecipitation and competition experiments
Cells were lysed in 50 mM Tris-HCl, pH 7.8, 150 mM NaCl, 0.5%   
NP-40 plus protease inhibitor cocktail (Roche), and 10 nM microcystin (LGC- 
Promotech) for 20 min on ice and clarified by a 12,000 g spin for 15 min 
at 4°C. Complexes were immunoprecipitated for 2 h at 4°C with anti-Flag 
(M2; Sigma-Aldrich) or anti-BubR1 (BD) antibody covalently coupled to pro-
tein G (Dynabeads; Invitrogen). After five washes in lysis buffer, proteins were 
eluted from beads by incubating for 5 min at 65°C in sample buffer. For the 
competition experiments, Cdc20 complexes were isolated using anti-Cdc20 
(H-7; Santa Cruz Biotechnology, Inc.) antibody. After the washes, beads with 
associated complexes were divided into several tubes, and 1–2 µM purified 
GST fusion protein was added to the beads and incubated in buffer A for   
2 h at 4°C. The supernatant containing the unbound GST proteins and pro-
teins released from the immunoprecipitated complexes were analyzed by 
immunoblotting. Beads were washed three times with buffer A, and the com-
plexes still associated eluted in sample buffer for 5 min at 65°C.
Immunoblotting
After electrophoresis on 4–12% gradient Bis-Tris acrylamide gels, proteins 
were transferred to a PVDF membrane. Membrane saturation and all of the 
following incubation steps were performed in 5% low fat milk in 0.1% PBS-
Tween. Anti-Flag (M2; Sigma-Aldrich), anti-GST (B-14; Santa Cruz Biotechnol-
ogy, Inc.), anti–cyclin A (Cancer Research UK), and anti-APC3 (BD) were 
used at 1:1,000. Anti-Cdc20 (Bethyl Laboratories), anti-BubR1 (Bethyl Labo-
ratories and BD), and anti-Cdk2 (Koop, 2007) were used at 1:500. Anti-
Cks1 (Invitrogen) was used at 1:150. Alexa Fluor 680 (Invitrogen)– and 
IRDye (800CW; LI-COR Biosources)-conjugated secondary antibodies were 
used at 1:5,000. The antibody signal was detected using the infrared imag-
ing system (Odyssey; LI-COR) for quantitative immunoblotting.
SAC-resistant degradation on a cyclin A–Cdc20 complex. This 
result strongly indicates that Cks1 mediates the recruitment of 
cyclin A to a phosphorylated APC/C subunit. Several APC/C 
subunits are phosphorylated during mitosis (Kraft et al., 2003; 
Steen et al., 2008), of which APC3 is most likely to bind Cks.
We conclude that two main factors contribute to the SAC-
resistant degradation of cyclin A. First, cyclin A can bind directly to 
Cdc20 with sufficient affinity to displace SAC proteins. Second, the 
Cks protein targets a cyclin A–Cdk complex to the APC/C in a man-
ner that allows Cdc20 bound to cyclin A to activate the APC/C.
Currently, we do not know exactly how cyclin A competes 
with the SAC proteins for Cdc20, in part because there is some 
disagreement over how the SAC proteins themselves bind Cdc20. 
We and others find that the majority of Cdc20 binds to an SAC 
complex with BubR1 and Bub3 but only a small fraction of Mad2, 
whereas others find that Mad2 forms a stoichiometric part of 
the complex (the reason for this discrepancy is unclear but 
may be attributable to the methods used to lyse the cells and iso-
late the SAC complexes or the methods used to calculate the 
amounts of protein in the complex; Nilsson et al., 2008; Herzog 
et al., 2009; Kulukian et al., 2009). However, there is general 
agreement that Mad2 is required for Cdc20 to bind to BubR1 
in vivo; therefore, if cyclin A blocks access to the Mad2-binding 
site on Cdc20, either sterically or by inducing a conformational 
change, this would prevent BubR1 from binding. Alternatively, 
as suggested by our in vitro assays, cyclin A and BubR1 them-
selves might compete for Cdc20.
Because both cyclin A and cyclin B1 require Cdc20 for 
their degradation, is the difference between them simply that   
cyclin A has a greater affinity for Cdc20, or might it bind to Cdc20 
in a different manner that allows SAC-independent destruction? 
We think the latter idea is unlikely because the SAC inhibits de-
struction of cyclin A (1–165) that binds Cdc20. Thus, our inter-
pretation is that cyclin A can be degraded by either or both of two 
pathways (Fig. 5 E). Cyclin A can either compete for Cdc20 be-
fore being targeted to the APC/C by Cks, or a cyclin A–Cdk–Cks 
complex could bind to an APC/C to which Cdc20 is already 
bound as part of an SAC complex, and, once bound, the N termi-
nus of cyclin A could displace the SAC proteins from Cdc20, 
thereby activating the APC/C.
Materials and methods
Cell culture and synchronization
HeLa cells were cultured in advanced DME (Invitrogen) supplemented with 2% 
fetal bovine serum. Cells were synchronized by a thymidine/aphidicolin pro-
tocol as previously described (Di Fiore and Pines, 2007). Cells were blocked 
with 2.5 mM thymidine (Sigma-Aldrich) for 24 h, released for 12 h, and 
blocked again with 5 µg/ml aphidicolin (Sigma-Aldrich) for 24 h. Cells were 
released into fresh medium. For prometaphase arrest, 0.1 µg/ml nocodazole 
(Sigma-Aldrich) or 100 nM taxol (Sigma-Aldrich) was added during release 
from a single thymidine block, and 12 h later, cells were either harvested by 
mitotic shake off or 10 µM MG132 (EMD) was added, and cells collected 
by mitotic shake off 2 h later. The HeLa-FRT cell lines (provided by S. Taylor, 
University of Manchester, Manchester, England, UK) were transfected using 
the FLIP-in system (Invitrogen) to generate stable inducible cell lines. Cells were 
induced with 1 µg/ml tetracycline (EMD) 12 h before harvesting.
Plasmids
Cyclin A and its mutants were cloned into a modified version of pCDNA5/
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APC/C purification and ubiquitylation assays
Taxol-treated HeLa cells were resuspended in 20 mM Hepes, pH 7.8, 175 mM 
NaCl, 2.5 mM MgCl2, 10% glycerol, 1 mM DTT, 1 mM PMSF, protease 
inhibitor cocktail (Roche), 2 µM ocadaic acid, 10 nM microcystin LR, and 
phosphatase inhibitor cocktail II (EMD) and ruptured using nitrogen cavita-
tion. APC/C was immunoprecipitated from 10 mg of extract using anti-APC4 
antibodies immobilized on protein G (Dynabeads; Invitrogen). Substrates 
were purified on Strep-Tactin beads (IBA) and radiolabeled with 
33P by phos-
phorylation of a muscle kinase tag (HMK) using protein kinase A (Sigma-
Aldrich). Ubiquitylation reactions were performed at 37°C in 15 µl of QPIP 
buffer (50 mM Pipes, pH 7.5, 100 mM NaCl, 2 mM MgCl2, 10% glycerol,   
1 mM DTT, and 1 mM EGTA) containing 5 µl APC4 beads, 300 nM E1, 
2.6 µM UbcH10, 150 µM ubiquitin, 1 µM BSA, 100 nM CDC20, 100 nM 
radiolabeled substrate, 2 mM ATP, 2.3 µM creatine kinase, and 10 mM cre-
atine phosphate as previously described (Garnett et al., 2009). For the com-
petition with cold (unlabeled) substrate, a 100 times excess over the labeled 
substrate was added to each reaction at time 0. Reactions were stopped with 
SDS sample buffer, processed for SDS-PAGE, and analyzed on a phospho-
imager (FLA-5000; Fujifilm).
Online supplemental material
Fig. S1 shows the strong reduction in Cdk2 binding of the cyclin A (1–165)– 
Venus-Cks1  protein  compared  with  full-length  cyclin  A.  Online  supple-
mental material is available at http://www.jcb.org/cgi/content/full/jcb 
.201001083/DC1.
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